School project · Delayed data · Not financial adviceTerms
SingularityViewAll companies

Stock research

AGENUS INC AGEN

Healthcare · Biotechnology

$7.43last close 2026-10-12 · market cap $335.55M · delayed data

Trailing returns

1M+7.06%
3M+121.79%
6M+87.63%
1Y+87.15%
5Y-93.29%

Basis: Adjusted daily closes.

What it does

Agenus Inc., a clinical-stage biotechnology company, discovers and develops immunotherapies for cancer and infectious diseases in the United States and internationally. It offers Retrocyte Display, an antibody expression platform for the identification of fully human and humanized monoclonal antibodies; and display technologies. It develops QS-21 Stimulon adjuvant, a saponin-based vaccine adjuvant.

Open AGEN in the live terminal →

Valuation, cost of capital, SEC filings, ownership and more, with the source named on every figure.

Post on XLinkedInEmail

Where these figures come from

Delayed data. Not financial advice. Figures are read from the sources above at the dates shown; nothing here is a recommendation. Disclosures · All companies